Einhorn Lawrence H, Rapoport Bernardo, Koeller Jim, Grunberg Steven M, Feyer Petra, Rittenberg Cynthia, Aapro Matti
Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN 46202-5289, USA.
Support Care Cancer. 2005 Feb;13(2):112-6. doi: 10.1007/s00520-004-0704-4. Epub 2004 Oct 9.
The objective of this paper is to evaluate the efficacy of modern antiemetic therapy for chemotherapy-induced nausea and vomiting for patients receiving multiple-day or high-dose chemotherapy. Published phase II and phase III studies as well as their personal experiences were evaluated by the authors to develop this consensus statement. The largest published experience with multiple-day chemotherapy is with 5-day cisplatin combination chemotherapy. The introduction of 5-HT3 antagonists greatly improved emetic control. However, day 4-5 nausea as well as delayed nausea and vomiting remains a clinical problem despite the inclusion of dexamethasone. A 5-HT3 antagonist plus dexamethasone is the preferred current option for patients receiving high-dose chemotherapy with stem cell transplant. However, the results do not appear as successful as for highly emetic standard-dose chemotherapy.
本文的目的是评估现代抗呕吐疗法对接受多日或高剂量化疗患者化疗引起的恶心和呕吐的疗效。作者评估了已发表的II期和III期研究及其个人经验，以制定本共识声明。关于多日化疗的最大规模已发表经验来自5天顺铂联合化疗。5-HT3拮抗剂的引入极大地改善了呕吐控制。然而，尽管使用了地塞米松，但第4 - 5天的恶心以及延迟性恶心和呕吐仍然是一个临床问题。对于接受高剂量化疗并进行干细胞移植的患者，5-HT3拮抗剂加地塞米松是目前的首选方案。然而，结果似乎不如高致吐性标准剂量化疗那样成功。
